Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Bristol-Myers Squibb CompanyNYSE: BMY

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $3.32B rose 152.6% year over year, ahead of the +83.1% change in trailing-twelve-month net income. Sequentially, it rose 23.8% from the prior quarter. Over 3 fiscal years it compounded at +3.6% a year.

Context

  • Net income amounted to 14.6% of revenue in FY2025, down 3.9 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 19 analysts of $13.22B (+87.4%) for the fiscal year ending Dec 2026, a slowdown from the +179.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.32B+23.8% QoQ
Last fiscal yearDec 2025
$7.06B+179.0% YoY
LTMJun 2026
$9.27B+83.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+152.6%+2.8%-149.8 pp
1 year+179.0%+87.4%-91.6 pp
3-year CAGR+3.6%+15.6%+12.0 pp
5-year CAGR+7.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
7.06B USD
Year-over-year change
+179.0%
4-year CAGR
+0.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BMY compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +83.1% is the 2nd highest of 11, against a peer median of +4.5%.
  • Net income amounts to 18.9% of revenue for BMY, versus a peer median of 17.1%.
BMY Competitors
Net Income for BMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.4%+32.5%22.9%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$9.27B USD+83.1%+3.6%18.9%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
ABBVAbbVie Inc.LTM Jun 2026$6.32B USD+66.4%-29.1%9.8%
GSKGSK plcLTM Jun 2026£5.62B GBP+41.0%+0.6%16.9%
GILDGilead Sciences, Inc.LTM Jun 2026$5.24B USD-17.0%+22.8%17.2%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding BMY) —+4.5%+11.1%17.1%

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.01B6.35B8.04B(8.93B)7.06B
Depreciation & Amortization10.69B10.28B9.76B9.6B4.01B
Deferred Income Tax(1.39B)(2.74B)(3.29B)(2.09B)(965M)
Stock-Based Compensation583M457M518M507M553M
Change in Working Capital(1.26B)(2.23B)(1.91B)810M(455M)
Accounts Receivables(1.05B)(663M)(995M)264M(295M)
Inventory13M(69M)(751M)(486M)(184M)
Accounts Payables245M109M198M184M(2M)
Other Working Capital(465M)(1.61B)(366M)848M26M
Other Non-Cash Items578M955M744M15.3B3.96B
Operating Cash Flow16.21B13.07B13.86B15.19B14.16B
Capital Expenditures(973M)(1.12B)(1.21B)(1.25B)(1.31B)
Acquisitions (Net)(862M)(2.98B)(260M)(20.72B)(2.87B)
Purchases of Investments(5.48B)(3.59B)(1.77B)(769M)(2B)
Sales of Investments6.78B6.63B948M1.39B2.05B
Other Investing Activities00000
Investing Cash Flow(538M)(1.06B)(2.3B)(21.35B)(4.13B)
Debt Repayment(6.18B)(5.31B)456M10.1B(5.18B)
Common Stock Issued000(106M)(128M)
Common Stock Repurchased(6.29B)(8B)(5.16B)00
Dividends Paid(4.4B)(4.63B)(4.74B)(4.86B)(5.05B)
Other Financing Activities641M984M27M00
Financing Cash Flow(16.22B)(16.96B)(9.42B)5.13B(10.35B)
Effect of Forex Changes(102M)(33M)45M(137M)187M
Net Change in Cash(657M)(4.99B)2.19B(1.17B)(137M)
Free Cash Flow15.23B11.95B12.65B13.94B12.85B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.